Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals

On 19 December 2016, Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals, under which, Third Venture Biopharma was granted the exclusive rights to develop and commercialize Olamkicept (an autoimmune drug of Ferring Pharmaceuticals) for autoimmune indications in Asia.



Olamkicept is a novel recombinant protein inhibitor of the interleukin-6 (IL-6) pathway.IL-6 is a key cytokine in the pathogenesis of autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. Two Phase I clinical studies on Olamkicept have been completed in Germany and Phase II clinical studies are ongoing abroad. This compound has a significant differentiation competitive advantage over existing IL-6 antibody drugs.

"Promising phase 1 clinical data on Olamkicep has been obtained. And we hope that through the further development of this innovative drug, we can drive Third Venture Biopharma to march into the R&D forefront of autoimmune drugs," said Jingwu Zang, President and CEO of Third Venture Biopharma.